Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,21898816,flow rate,"Separation was achieved on a CN column (200 mm×4.6 mm) using acetonitrile-10 mM orthophosphoric acid containing 1 mL/L triethylamine (45:55, v/v) at a flow rate of 1 mL/min.",A new HPLC method with fluorescence detection for the determination of memantine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21898816/),[ml] / [min],1,6200,DB01043,Memantine
,21898816,Limit of detection,"Limit of detection and limit of quantification were found to be 0.3 and 1.0 ng/mL, respectively.",A new HPLC method with fluorescence detection for the determination of memantine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21898816/),[ng] / [ml],0.3,6201,DB01043,Memantine
,21898816,limit of quantification,"Limit of detection and limit of quantification were found to be 0.3 and 1.0 ng/mL, respectively.",A new HPLC method with fluorescence detection for the determination of memantine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21898816/),[ng] / [ml],1.0,6202,DB01043,Memantine
,21898816,recovery,Average recovery was also found to be around 94%.,A new HPLC method with fluorescence detection for the determination of memantine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21898816/),%,94,6203,DB01043,Memantine
,34175447,effective detection limit,The effective detection limit of this method was 1.95-1000 ng·mL-1.,"Pharmacokinetic and tissue distribution study of ZCY-15, a novel compound against Alzheimer's disease, in rats by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34175447/),[ng] / [ml],1.95-1000,19957,DB01043,Memantine
,34175447,whole analysis time,The whole analysis time was 3.6 min per sample.,"Pharmacokinetic and tissue distribution study of ZCY-15, a novel compound against Alzheimer's disease, in rats by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34175447/),[min] / [sample],3.6,19958,DB01043,Memantine
,17553649,limits of detection,"The limits of detection and quantification were 20 and 50 ng/ml for the analytes, respectively.",New method for high-performance liquid chromatographic determination of amantadine and its analogues in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17553649/),[ng] / [ml],20,36901,DB01043,Memantine
,17553649,limits of detection,"The limits of detection and quantification were 20 and 50 ng/ml for the analytes, respectively.",New method for high-performance liquid chromatographic determination of amantadine and its analogues in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17553649/),[ng] / [ml],50,36902,DB01043,Memantine
,23371894,clearance,The average clearance was 5.2 L/h with a 27 % inter-individual variability (percentage coefficient of variation).,Population pharmacokinetic study of memantine: effects of clinical and genetic factors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23371894/),[l] / [h],5.2,38303,DB01043,Memantine
,28766500,C<sub>max</sub>,"The evaluated pharmacokinetic parameters (test vs. reference) including C<sub>max</sub> (18 ± 3.2 vs. 17.8 ± 3.4), AUC<sub>0-t</sub> (1,188.5 ± 222.2 vs. 1,170.9 ± 135.7), and AUC<sub>0-∞</sub> (1,353.3 ± 258.6 vs. 1,291.3 ± 136.7) values were assessed for bioequivalence based on current guidelines.",A bioequivalence study of two memantine formulations in healthy Chinese male volunteers . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28766500/),,18,60388,DB01043,Memantine
,28766500,C<sub>max</sub>,"The evaluated pharmacokinetic parameters (test vs. reference) including C<sub>max</sub> (18 ± 3.2 vs. 17.8 ± 3.4), AUC<sub>0-t</sub> (1,188.5 ± 222.2 vs. 1,170.9 ± 135.7), and AUC<sub>0-∞</sub> (1,353.3 ± 258.6 vs. 1,291.3 ± 136.7) values were assessed for bioequivalence based on current guidelines.",A bioequivalence study of two memantine formulations in healthy Chinese male volunteers . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28766500/),,17.8,60389,DB01043,Memantine
,28766500,AUC<sub>0-t</sub>,"The evaluated pharmacokinetic parameters (test vs. reference) including C<sub>max</sub> (18 ± 3.2 vs. 17.8 ± 3.4), AUC<sub>0-t</sub> (1,188.5 ± 222.2 vs. 1,170.9 ± 135.7), and AUC<sub>0-∞</sub> (1,353.3 ± 258.6 vs. 1,291.3 ± 136.7) values were assessed for bioequivalence based on current guidelines.",A bioequivalence study of two memantine formulations in healthy Chinese male volunteers . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28766500/),,"1,188.5",60390,DB01043,Memantine
,28766500,AUC<sub>0-t</sub>,"The evaluated pharmacokinetic parameters (test vs. reference) including C<sub>max</sub> (18 ± 3.2 vs. 17.8 ± 3.4), AUC<sub>0-t</sub> (1,188.5 ± 222.2 vs. 1,170.9 ± 135.7), and AUC<sub>0-∞</sub> (1,353.3 ± 258.6 vs. 1,291.3 ± 136.7) values were assessed for bioequivalence based on current guidelines.",A bioequivalence study of two memantine formulations in healthy Chinese male volunteers . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28766500/),,"1,170.9",60391,DB01043,Memantine
,28766500,AUC<sub>0-∞</sub>,"The evaluated pharmacokinetic parameters (test vs. reference) including C<sub>max</sub> (18 ± 3.2 vs. 17.8 ± 3.4), AUC<sub>0-t</sub> (1,188.5 ± 222.2 vs. 1,170.9 ± 135.7), and AUC<sub>0-∞</sub> (1,353.3 ± 258.6 vs. 1,291.3 ± 136.7) values were assessed for bioequivalence based on current guidelines.",A bioequivalence study of two memantine formulations in healthy Chinese male volunteers . ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28766500/),,"1,353.3",60392,DB01043,Memantine
,28766500,AUC<sub>0-∞</sub>,"The evaluated pharmacokinetic parameters (test vs. reference) including C<sub>max</sub> (18 ± 3.2 vs. 17.8 ± 3.4), AUC<sub>0-t</sub> (1,188.5 ± 222.2 vs. 1,170.9 ± 135.7), and AUC<sub>0-∞</sub> (1,353.3 ± 258.6 vs. 1,291.3 ± 136.7) values were assessed for bioequivalence based on current guidelines.",A bioequivalence study of two memantine formulations in healthy Chinese male volunteers . ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28766500/),,"1,291.3",60393,DB01043,Memantine
,18814193,total chromatographic run time,"The total chromatographic run time was 3.0 min and the elution of PPX and IS occurred at approximately 2.32 and 2.52, respectively.",Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of pramipexole in human plasma: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18814193/),min,3.0,63947,DB01043,Memantine
,18814193,ion transitions,The MS/MS ion transitions monitored were 212.10 --> 153.10 for PPX and 180.20 --> 107.30 for IS.,Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of pramipexole in human plasma: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18814193/),,212.10,63948,DB01043,Memantine
,18814193,ion transitions,The MS/MS ion transitions monitored were 212.10 --> 153.10 for PPX and 180.20 --> 107.30 for IS.,Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of pramipexole in human plasma: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18814193/),,153.10,63949,DB01043,Memantine
,18814193,ion transitions,The MS/MS ion transitions monitored were 212.10 --> 153.10 for PPX and 180.20 --> 107.30 for IS.,Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of pramipexole in human plasma: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18814193/),,180.20,63950,DB01043,Memantine
,18589560,half-lives,The findings suggest that even for drugs with half-lives between 24 and 60 h and thus shorter than those of donepezil and memantine an AUC truncated to 48 h post dose can be successfully used for the assessment of bioequivalence as this sample collection time ensures a proper comparison of the absorption process as recommended in the CPMP Note for Guidance on the Investigation of Bioavailability and Bioequivalence.,The use of truncated area under the curves in the bioequivalence evaluation of long half-life drugs. Studies with donepezil and memantine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18589560/),h,24 and 60,79119,DB01043,Memantine
,25573540,binding affinity,The altered pharmacokinetics of a synthetic ozonide in rats has been attributed to an unusually high-binding affinity (2.3 × 10(6) M(-1) ) between the drug and sulfobutylether7 -β-cyclodextrin (SBE7 -β-CD) with further studies suggesting a significant binding contribution from the adamantane ring.,The effect of intravenous sulfobutylether7 -β-cyclodextrin on the pharmacokinetics of a series of adamantane-containing compounds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573540/),1/[M],2.3 × 10(6),82026,DB01043,Memantine
,25573540,binding constants,SBE7 -β-CD binding constants for the compounds were within the typical range for drug-like molecules (10(2) -10(4) M(-1) ).,The effect of intravenous sulfobutylether7 -β-cyclodextrin on the pharmacokinetics of a series of adamantane-containing compounds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573540/),1/[M],10(2) -10(4),82027,DB01043,Memantine
,31978146,DF,"Single dose of memantine significantly increased DF, from basic values (1.65±1.05 cycles per min.) to 2.86 cpm after 30 min.",The pharmacokinetic parameters and the effect of a single and repeated doses of memantine on gastric myoelectric activity in experimental pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31978146/),[cycles] / [min],1.65,95293,DB01043,Memantine
,31978146,DF,"Single dose of memantine significantly increased DF, from basic values (1.65±1.05 cycles per min.) to 2.86 cpm after 30 min.",The pharmacokinetic parameters and the effect of a single and repeated doses of memantine on gastric myoelectric activity in experimental pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31978146/),cpm,2.86,95294,DB01043,Memantine
,31978146,basal power,"In comparison with a single dose, basal power was significantly higher after repetitively administrated memantine (median 3940; IQR 695-15023 μV^2; p<0.001).",The pharmacokinetic parameters and the effect of a single and repeated doses of memantine on gastric myoelectric activity in experimental pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31978146/),μv^2,3940,95295,DB01043,Memantine
,23513957,LOD,"LOD and LOQ were found to be 0.3 and 1.0 ng/mL, respectively.",A new HPLC method with fluorescence detection for the determination of memantine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23513957/),[ng] / [ml],0.3,96263,DB01043,Memantine
,23513957,LOQ,"LOD and LOQ were found to be 0.3 and 1.0 ng/mL, respectively.",A new HPLC method with fluorescence detection for the determination of memantine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23513957/),[ng] / [ml],1.0,96264,DB01043,Memantine
,21594878,signal-to-noise ratios,"The limits of detection and quantitation at signal-to-noise ratios of 3 and 10 were 2.0 and 6.6 ng/mL, respectively.",Determination of memantine in rat plasma by HPLC-fluorescence method and its application to study of the pharmacokinetic interaction between memantine and methazolamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21594878/),[ng] / [ml],3,99760,DB01043,Memantine
,21594878,signal-to-noise ratios,"The limits of detection and quantitation at signal-to-noise ratios of 3 and 10 were 2.0 and 6.6 ng/mL, respectively.",Determination of memantine in rat plasma by HPLC-fluorescence method and its application to study of the pharmacokinetic interaction between memantine and methazolamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21594878/),[ng] / [ml],10,99761,DB01043,Memantine
,21594878,signal-to-noise ratios,"The limits of detection and quantitation at signal-to-noise ratios of 3 and 10 were 2.0 and 6.6 ng/mL, respectively.",Determination of memantine in rat plasma by HPLC-fluorescence method and its application to study of the pharmacokinetic interaction between memantine and methazolamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21594878/),[ng] / [ml],2.0,99762,DB01043,Memantine
,21594878,signal-to-noise ratios,"The limits of detection and quantitation at signal-to-noise ratios of 3 and 10 were 2.0 and 6.6 ng/mL, respectively.",Determination of memantine in rat plasma by HPLC-fluorescence method and its application to study of the pharmacokinetic interaction between memantine and methazolamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21594878/),[ng] / [ml],6.6,99763,DB01043,Memantine
,15266045,Percent maximum inhibition,Percent maximum inhibition of AChE activity (mean +/- SD) by donepezil was 77.8 +/- 7.3% and not significantly different upon coadministration of a single dose of memantine (81.1 +/- 5.7%).,Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15266045/),%,77.8,110075,DB01043,Memantine
,15266045,Percent maximum inhibition,Percent maximum inhibition of AChE activity (mean +/- SD) by donepezil was 77.8 +/- 7.3% and not significantly different upon coadministration of a single dose of memantine (81.1 +/- 5.7%).,Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15266045/),%,81.1,110076,DB01043,Memantine
,28212021,Ki,"It has high affinity at human 5-HT6R (Ki = 2.04 nM) and selectivity over 100 target sites which include receptors, enzymes, peptides, growth factors, ion channels, steroids, immunological factors, second messengers, and prostaglandins.","Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT6) Receptor Antagonist for Potential Treatment of Alzheimer's Disease. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28212021/),nM,2.04,117337,DB01043,Memantine
,24597794,relative,"High vitreous bioavailability after PST was observed, and the relative vitreous bioavailability of memantine following PST administration (0.53%) was greater than for intravenous administration (0.02%).","Vitreous pharmacokinetics and bioavailability of memantine after subtenon, intravenous, and intravitreal administration in rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24597794/),%,0.53,135803,DB01043,Memantine
,24597794,relative,"High vitreous bioavailability after PST was observed, and the relative vitreous bioavailability of memantine following PST administration (0.53%) was greater than for intravenous administration (0.02%).","Vitreous pharmacokinetics and bioavailability of memantine after subtenon, intravenous, and intravitreal administration in rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24597794/),%,0.02,135804,DB01043,Memantine
,16413248,steady-state maximum concentration,"Simulations predicted steady-state maximum concentration values of 82 ng/mL (95% CI, 70-95 ng/mL), 85 ng/mL (95% CI, 70-101 ng/mL), and 128 ng/mL (95% CI, 109-147 ng/mL) in healthy subjects, those with mild renal impairment, and those with moderate renal impairment, respectively, for the recommended dosing regimen of 10 mg twice daily; for subjects with severe renal impairment, a steady-state maximum concentration value of 84 ng/mL (95% CI, 68-101 ng/mL) was predicted for a dosing regimen of 5 mg twice daily.",Pharmacokinetic study of memantine in healthy and renally impaired subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413248/),[ng] / [ml],82,150674,DB01043,Memantine
,16413248,steady-state maximum concentration,"Simulations predicted steady-state maximum concentration values of 82 ng/mL (95% CI, 70-95 ng/mL), 85 ng/mL (95% CI, 70-101 ng/mL), and 128 ng/mL (95% CI, 109-147 ng/mL) in healthy subjects, those with mild renal impairment, and those with moderate renal impairment, respectively, for the recommended dosing regimen of 10 mg twice daily; for subjects with severe renal impairment, a steady-state maximum concentration value of 84 ng/mL (95% CI, 68-101 ng/mL) was predicted for a dosing regimen of 5 mg twice daily.",Pharmacokinetic study of memantine in healthy and renally impaired subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413248/),[ng] / [ml],85,150675,DB01043,Memantine
,16413248,steady-state maximum concentration,"Simulations predicted steady-state maximum concentration values of 82 ng/mL (95% CI, 70-95 ng/mL), 85 ng/mL (95% CI, 70-101 ng/mL), and 128 ng/mL (95% CI, 109-147 ng/mL) in healthy subjects, those with mild renal impairment, and those with moderate renal impairment, respectively, for the recommended dosing regimen of 10 mg twice daily; for subjects with severe renal impairment, a steady-state maximum concentration value of 84 ng/mL (95% CI, 68-101 ng/mL) was predicted for a dosing regimen of 5 mg twice daily.",Pharmacokinetic study of memantine in healthy and renally impaired subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413248/),[ng] / [ml],128,150676,DB01043,Memantine
,16413248,steady-state maximum concentration,"Simulations predicted steady-state maximum concentration values of 82 ng/mL (95% CI, 70-95 ng/mL), 85 ng/mL (95% CI, 70-101 ng/mL), and 128 ng/mL (95% CI, 109-147 ng/mL) in healthy subjects, those with mild renal impairment, and those with moderate renal impairment, respectively, for the recommended dosing regimen of 10 mg twice daily; for subjects with severe renal impairment, a steady-state maximum concentration value of 84 ng/mL (95% CI, 68-101 ng/mL) was predicted for a dosing regimen of 5 mg twice daily.",Pharmacokinetic study of memantine in healthy and renally impaired subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413248/),[ng] / [ml],84,150677,DB01043,Memantine
,10411561,half-life,In serum the half-life of MRZ 2/576 (30 mg/kg) was also increased by coadministration of probenecid from 15.6 +/- 1.3 to 40.6 +/- 6.0 min.,The role of probenecid-sensitive organic acid transport in the pharmacokinetics of N-methyl-D-aspartate receptor antagonists acting at the glycine(B)-site: microdialysis and maximum electroshock seizures studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10411561/),min,15.6,156588,DB01043,Memantine
,10411561,half-life,In serum the half-life of MRZ 2/576 (30 mg/kg) was also increased by coadministration of probenecid from 15.6 +/- 1.3 to 40.6 +/- 6.0 min.,The role of probenecid-sensitive organic acid transport in the pharmacokinetics of N-methyl-D-aspartate receptor antagonists acting at the glycine(B)-site: microdialysis and maximum electroshock seizures studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10411561/),min,40.6,156589,DB01043,Memantine
,17103338,rate of perfusion,"Fresh bovine eyes were prepared by exposing and cannulating one ciliary artery, placing the eye into a perfusion chamber and slowly increasing the rate of perfusion to 1.0 ml/min.",Pharmacokinetics and disposition of memantine in the arterially perfused bovine eye. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17103338/),[ml] / [min],1.0,158845,DB01043,Memantine
<,22307216,half-life,"In rats and mice, memantine had a short half-life (<4 h) and steep Cmax/Cmin ratios (>100).",Pharmacokinetics of memantine in rats and mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22307216/),h,4,163762,DB01043,Memantine
>,22307216,Cmax/Cmin ratios,"In rats and mice, memantine had a short half-life (<4 h) and steep Cmax/Cmin ratios (>100).",Pharmacokinetics of memantine in rats and mice. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22307216/),,100,163763,DB01043,Memantine
,22307216,half-life,"In the human, the half-life of memantine was reported to be very long (60-80 h) with a Cmax/Cmin ratio at steady state concentrations of ~1.5.",Pharmacokinetics of memantine in rats and mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22307216/),h,60-80,163764,DB01043,Memantine
,22307216,Cmax/Cmin ratio at steady state concentrations,"In the human, the half-life of memantine was reported to be very long (60-80 h) with a Cmax/Cmin ratio at steady state concentrations of ~1.5.",Pharmacokinetics of memantine in rats and mice. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22307216/),,1.5,163765,DB01043,Memantine
,21179320,flow rate,"The mobile phase was composed of a mixture of acetonitrile and 0.025 M phosphate buffer (50:50, v/v, pH=4.6) with a flow rate of 2.5 mLmin(â1).",Sensitive and rapid HPLC method for determination of memantine in human plasma using OPA derivatization and fluorescence detection: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21179320/),mlmin(â1),2.5,168136,DB01043,Memantine
,21179320,analytical recovery,The method involves simple extraction procedure and analytical recovery was 82.8Â 0.9%.,Sensitive and rapid HPLC method for determination of memantine in human plasma using OPA derivatization and fluorescence detection: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21179320/),%,82.8,168137,DB01043,Memantine
,7813574,time to reach this maximum (tmax),"The maximal concentrations (Cmax) differed dose dependently, whereas the time to reach this maximum (tmax) was almost identical (68.5 +/- 3.4 min).",Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat--a pharmacokinetic microdialysis study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7813574/),min,68.5,172840,DB01043,Memantine
,7813574,half-life,From the flat elimination profile a half-life of 2.8 +/- 0.5 h (range 2-3.4 h) was calculated.,Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat--a pharmacokinetic microdialysis study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7813574/),h,2.8,172841,DB01043,Memantine
,22863669,maximum plasma concentration (C(max)),"Mean memantine maximum plasma concentration (C(max)) was similar in the groups (12.66, 17.25, 15.75, and 15.83 ng/mL, respectively), as was mean time to C(max) (6.2, 5.2, 4.3, and 5.4 h, respectively).",Effect of renal impairment on the pharmacokinetics of memantine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22863669/),[ng] / [ml],12.66,181989,DB01043,Memantine
,22863669,maximum plasma concentration (C(max)),"Mean memantine maximum plasma concentration (C(max)) was similar in the groups (12.66, 17.25, 15.75, and 15.83 ng/mL, respectively), as was mean time to C(max) (6.2, 5.2, 4.3, and 5.4 h, respectively).",Effect of renal impairment on the pharmacokinetics of memantine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22863669/),[ng] / [ml],17.25,181990,DB01043,Memantine
,22863669,maximum plasma concentration (C(max)),"Mean memantine maximum plasma concentration (C(max)) was similar in the groups (12.66, 17.25, 15.75, and 15.83 ng/mL, respectively), as was mean time to C(max) (6.2, 5.2, 4.3, and 5.4 h, respectively).",Effect of renal impairment on the pharmacokinetics of memantine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22863669/),[ng] / [ml],15.75,181991,DB01043,Memantine
,22863669,maximum plasma concentration (C(max)),"Mean memantine maximum plasma concentration (C(max)) was similar in the groups (12.66, 17.25, 15.75, and 15.83 ng/mL, respectively), as was mean time to C(max) (6.2, 5.2, 4.3, and 5.4 h, respectively).",Effect of renal impairment on the pharmacokinetics of memantine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22863669/),[ng] / [ml],15.83,181992,DB01043,Memantine
,22863669,time to C(max),"Mean memantine maximum plasma concentration (C(max)) was similar in the groups (12.66, 17.25, 15.75, and 15.83 ng/mL, respectively), as was mean time to C(max) (6.2, 5.2, 4.3, and 5.4 h, respectively).",Effect of renal impairment on the pharmacokinetics of memantine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22863669/),h,6.2,181993,DB01043,Memantine
,22863669,time to C(max),"Mean memantine maximum plasma concentration (C(max)) was similar in the groups (12.66, 17.25, 15.75, and 15.83 ng/mL, respectively), as was mean time to C(max) (6.2, 5.2, 4.3, and 5.4 h, respectively).",Effect of renal impairment on the pharmacokinetics of memantine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22863669/),h,5.2,181994,DB01043,Memantine
,22863669,time to C(max),"Mean memantine maximum plasma concentration (C(max)) was similar in the groups (12.66, 17.25, 15.75, and 15.83 ng/mL, respectively), as was mean time to C(max) (6.2, 5.2, 4.3, and 5.4 h, respectively).",Effect of renal impairment on the pharmacokinetics of memantine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22863669/),h,4.3,181995,DB01043,Memantine
,22863669,time to C(max),"Mean memantine maximum plasma concentration (C(max)) was similar in the groups (12.66, 17.25, 15.75, and 15.83 ng/mL, respectively), as was mean time to C(max) (6.2, 5.2, 4.3, and 5.4 h, respectively).",Effect of renal impairment on the pharmacokinetics of memantine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22863669/),h,5.4,181996,DB01043,Memantine
,22863669,plasma elimination half-life,"Mean memantine plasma elimination half-life increased according to increasing renal impairment (61.15, 83.00, 100.13, and 124.31 h, respectively), while mean cumulative urinary recovery of unchanged memantine in 72 h after dosing decreased according to increasing renal impairment (33.68%, 33.47%, 23.60%, and 16.17%, respectively).",Effect of renal impairment on the pharmacokinetics of memantine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22863669/),h,61.15,181997,DB01043,Memantine
,22863669,plasma elimination half-life,"Mean memantine plasma elimination half-life increased according to increasing renal impairment (61.15, 83.00, 100.13, and 124.31 h, respectively), while mean cumulative urinary recovery of unchanged memantine in 72 h after dosing decreased according to increasing renal impairment (33.68%, 33.47%, 23.60%, and 16.17%, respectively).",Effect of renal impairment on the pharmacokinetics of memantine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22863669/),h,83.00,181998,DB01043,Memantine
,22863669,plasma elimination half-life,"Mean memantine plasma elimination half-life increased according to increasing renal impairment (61.15, 83.00, 100.13, and 124.31 h, respectively), while mean cumulative urinary recovery of unchanged memantine in 72 h after dosing decreased according to increasing renal impairment (33.68%, 33.47%, 23.60%, and 16.17%, respectively).",Effect of renal impairment on the pharmacokinetics of memantine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22863669/),h,100.13,181999,DB01043,Memantine
,22863669,plasma elimination half-life,"Mean memantine plasma elimination half-life increased according to increasing renal impairment (61.15, 83.00, 100.13, and 124.31 h, respectively), while mean cumulative urinary recovery of unchanged memantine in 72 h after dosing decreased according to increasing renal impairment (33.68%, 33.47%, 23.60%, and 16.17%, respectively).",Effect of renal impairment on the pharmacokinetics of memantine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22863669/),h,124.31,182000,DB01043,Memantine
,22863669,plasma elimination half-life,"Mean memantine plasma elimination half-life increased according to increasing renal impairment (61.15, 83.00, 100.13, and 124.31 h, respectively), while mean cumulative urinary recovery of unchanged memantine in 72 h after dosing decreased according to increasing renal impairment (33.68%, 33.47%, 23.60%, and 16.17%, respectively).",Effect of renal impairment on the pharmacokinetics of memantine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22863669/),%,33,182001,DB01043,Memantine
,32765924,m/z,"The target fragment ions were m/z 525.3 ⟶ 449.5 for PF, 336.2 ⟶ 320.2 for BBR, and 180.1 ⟶ 163.1 for IS.",Simultaneous Determination of Multiple Active Components from Bushen Pills and Application in a Pharmacokinetic Study in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32765924/),⟶,525.3,200578,DB01043,Memantine
,32765924,m/z,"The target fragment ions were m/z 525.3 ⟶ 449.5 for PF, 336.2 ⟶ 320.2 for BBR, and 180.1 ⟶ 163.1 for IS.",Simultaneous Determination of Multiple Active Components from Bushen Pills and Application in a Pharmacokinetic Study in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32765924/),⟶,449.5,200579,DB01043,Memantine
,32765924,m/z,"The target fragment ions were m/z 525.3 ⟶ 449.5 for PF, 336.2 ⟶ 320.2 for BBR, and 180.1 ⟶ 163.1 for IS.",Simultaneous Determination of Multiple Active Components from Bushen Pills and Application in a Pharmacokinetic Study in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32765924/),⟶,336.2,200580,DB01043,Memantine
,32765924,m/z,"The target fragment ions were m/z 525.3 ⟶ 449.5 for PF, 336.2 ⟶ 320.2 for BBR, and 180.1 ⟶ 163.1 for IS.",Simultaneous Determination of Multiple Active Components from Bushen Pills and Application in a Pharmacokinetic Study in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32765924/),,320.2,200581,DB01043,Memantine
,32765924,m/z,"The target fragment ions were m/z 525.3 ⟶ 449.5 for PF, 336.2 ⟶ 320.2 for BBR, and 180.1 ⟶ 163.1 for IS.",Simultaneous Determination of Multiple Active Components from Bushen Pills and Application in a Pharmacokinetic Study in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32765924/),⟶,180.1,200582,DB01043,Memantine
,32765924,m/z,"The target fragment ions were m/z 525.3 ⟶ 449.5 for PF, 336.2 ⟶ 320.2 for BBR, and 180.1 ⟶ 163.1 for IS.",Simultaneous Determination of Multiple Active Components from Bushen Pills and Application in a Pharmacokinetic Study in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32765924/),,163.1,200583,DB01043,Memantine
,26310825,bioavailability,"Memantine bioavailability was 41 and 63% for oral and patch administration, respectively.",Pharmacokinetics of Memantine after a Single and Multiple Dose of Oral and Patch Administration in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26310825/),%,41,210365,DB01043,Memantine
,26310825,bioavailability,"Memantine bioavailability was 41 and 63% for oral and patch administration, respectively.",Pharmacokinetics of Memantine after a Single and Multiple Dose of Oral and Patch Administration in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26310825/),%,63,210366,DB01043,Memantine
,30928488,bioavailability,"In the dog model, relative memantine bioavailability approaches 100% with sustained plasma levels of memantine over seven days and profiles that can be tuned by varying components of the formulation.",A pharmaceutical answer to nonadherence: Once weekly oral memantine for Alzheimer's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30928488/),%,100,215744,DB01043,Memantine
,34218083,IC50,"Among them, compound B401 significantly improved the inhibition potency with human and murine sEH IC50 values as 0.4 nM and 0.5 nM, respectively.",Discovery of memantyl urea derivatives as potent soluble epoxide hydrolase inhibitors against lipopolysaccharide-induced sepsis. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34218083/),nM,0.4,226951,DB01043,Memantine
,34218083,IC50,"Among them, compound B401 significantly improved the inhibition potency with human and murine sEH IC50 values as 0.4 nM and 0.5 nM, respectively.",Discovery of memantyl urea derivatives as potent soluble epoxide hydrolase inhibitors against lipopolysaccharide-induced sepsis. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34218083/),nM,0.5,226952,DB01043,Memantine
,1436383,ED50,"Memantine increased the threshold for electroconvulsions, when administered at 1.0-6.0 mg/kg (i.p.) and given in subthreshold doses of 0.0156, 0.0625, 0.125 and 0.5 mg/kg (i.p.) potentiated the protective efficacy of valproate, against maximal electroshock (50 mA)-induced seizures in mice, lowering the ED50 from 235 to 197, 172, 164 and 130 mg/kg, respectively.",Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1436383/),[mg] / [kg],235,230125,DB01043,Memantine
,1436383,ED50,"Memantine increased the threshold for electroconvulsions, when administered at 1.0-6.0 mg/kg (i.p.) and given in subthreshold doses of 0.0156, 0.0625, 0.125 and 0.5 mg/kg (i.p.) potentiated the protective efficacy of valproate, against maximal electroshock (50 mA)-induced seizures in mice, lowering the ED50 from 235 to 197, 172, 164 and 130 mg/kg, respectively.",Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1436383/),[mg] / [kg],197,230126,DB01043,Memantine
,1436383,ED50,"Memantine increased the threshold for electroconvulsions, when administered at 1.0-6.0 mg/kg (i.p.) and given in subthreshold doses of 0.0156, 0.0625, 0.125 and 0.5 mg/kg (i.p.) potentiated the protective efficacy of valproate, against maximal electroshock (50 mA)-induced seizures in mice, lowering the ED50 from 235 to 197, 172, 164 and 130 mg/kg, respectively.",Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1436383/),[mg] / [kg],172,230127,DB01043,Memantine
,1436383,ED50,"Memantine increased the threshold for electroconvulsions, when administered at 1.0-6.0 mg/kg (i.p.) and given in subthreshold doses of 0.0156, 0.0625, 0.125 and 0.5 mg/kg (i.p.) potentiated the protective efficacy of valproate, against maximal electroshock (50 mA)-induced seizures in mice, lowering the ED50 from 235 to 197, 172, 164 and 130 mg/kg, respectively.",Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1436383/),[mg] / [kg],164,230128,DB01043,Memantine
,1436383,ED50,"Memantine increased the threshold for electroconvulsions, when administered at 1.0-6.0 mg/kg (i.p.) and given in subthreshold doses of 0.0156, 0.0625, 0.125 and 0.5 mg/kg (i.p.) potentiated the protective efficacy of valproate, against maximal electroshock (50 mA)-induced seizures in mice, lowering the ED50 from 235 to 197, 172, 164 and 130 mg/kg, respectively.",Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1436383/),[mg] / [kg],130,230129,DB01043,Memantine
,1436383,ED50,"Trihexyphenidyl, applied in doses of 30 and 50 mg/kg (i.p.), did not influence the electroconvulsive threshold per se but when combined with valproate, strongly enhanced its anticonvulsant activity against maximal electroshock-induced seizures lowering the ED50 from 206 to 103 and 46 mg/kg, respectively.",Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1436383/),[mg] / [kg],206,230130,DB01043,Memantine
,1436383,ED50,"Trihexyphenidyl, applied in doses of 30 and 50 mg/kg (i.p.), did not influence the electroconvulsive threshold per se but when combined with valproate, strongly enhanced its anticonvulsant activity against maximal electroshock-induced seizures lowering the ED50 from 206 to 103 and 46 mg/kg, respectively.",Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1436383/),[mg] / [kg],103,230131,DB01043,Memantine
,1436383,ED50,"Trihexyphenidyl, applied in doses of 30 and 50 mg/kg (i.p.), did not influence the electroconvulsive threshold per se but when combined with valproate, strongly enhanced its anticonvulsant activity against maximal electroshock-induced seizures lowering the ED50 from 206 to 103 and 46 mg/kg, respectively.",Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1436383/),[mg] / [kg],46,230132,DB01043,Memantine
,26280281,flow rate,"The analytes were separated on C18 reversed phase column with mobile phase consisting of a mixture of methanol and 10mM ammonium acetate, pH 5 (92:8 v/v) at a flow rate of 0.7mL/min.",Development of an LC-MS/MS method for simultaneous determination of memantine and donepezil in rat plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26280281/),[ml] / [min],0.7,240406,DB01043,Memantine
greater,26280281,recovery,The mean recovery of MM and DPZ was found to be greater than 80%.,Development of an LC-MS/MS method for simultaneous determination of memantine and donepezil in rat plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26280281/),%,80,240407,DB01043,Memantine
,18498913,recoveries,"The mean recoveries of the 0.4, 20.0, and 180.0 ng/mL levels were 78.87%, 81.55%, and 81.98%, respectively.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),%,78.87,254806,DB01043,Memantine
,18498913,recoveries,"The mean recoveries of the 0.4, 20.0, and 180.0 ng/mL levels were 78.87%, 81.55%, and 81.98%, respectively.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),%,81.55,254807,DB01043,Memantine
,18498913,recoveries,"The mean recoveries of the 0.4, 20.0, and 180.0 ng/mL levels were 78.87%, 81.55%, and 81.98%, respectively.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),%,81.98,254808,DB01043,Memantine
,18498913,C(max),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[ng] / [ml],6.20,254809,DB01043,Memantine
,18498913,C(max),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[ng] / [ml],11.60,254810,DB01043,Memantine
,18498913,C(max),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[ng] / [ml],25.34,254811,DB01043,Memantine
,18498913,T(max),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,5.70,254812,DB01043,Memantine
,18498913,T(max),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,6.00,254813,DB01043,Memantine
,18498913,T(max),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,6.89,254814,DB01043,Memantine
,18498913,AUC(0-t),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[h·ng] / [ml],486.19,254815,DB01043,Memantine
,18498913,AUC(0-t),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[h·ng] / [ml],889.32,254816,DB01043,Memantine
,18498913,AUC(0-t),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[h·ng] / [ml],1772.91,254817,DB01043,Memantine
,18498913,AUC(0-infinity),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[h·ng] / [ml],540.05,254818,DB01043,Memantine
,18498913,AUC(0-infinity),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[h·ng] / [ml],932.07,254819,DB01043,Memantine
,18498913,AUC(0-infinity),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[h·ng] / [ml],1853.29,254820,DB01043,Memantine
,18498913,t(1/2),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,66.86,254821,DB01043,Memantine
,18498913,t(1/2),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,63.57,254822,DB01043,Memantine
,18498913,t(1/2),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,62.06,254823,DB01043,Memantine
,18498913,MRT,"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),,99.37,254824,DB01043,Memantine
,18498913,MRT,"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),,91.73,254825,DB01043,Memantine
,18498913,T(max),"The main pharmacokinetic parameters found for memantine at doses of 5 mg once daily for 14 days were as follows: T(max), 6.80 (2.46) h; C(ssmax), 19.69 (2.00) ng/mL; C(ssmin), 12.76 (2.80) ng/mL; C(ssav), 16.10 (2.46) ng/mL; t(1/2), 64.57 (15.78) h; MRT, 93.17 (23.38) h; AUC(ss),386.37 (59.00) ng x h/mL; and DF, 44.47% (15.27%).",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,6.80,254826,DB01043,Memantine
,18498913,C(ssmax),"The main pharmacokinetic parameters found for memantine at doses of 5 mg once daily for 14 days were as follows: T(max), 6.80 (2.46) h; C(ssmax), 19.69 (2.00) ng/mL; C(ssmin), 12.76 (2.80) ng/mL; C(ssav), 16.10 (2.46) ng/mL; t(1/2), 64.57 (15.78) h; MRT, 93.17 (23.38) h; AUC(ss),386.37 (59.00) ng x h/mL; and DF, 44.47% (15.27%).",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[ng] / [ml],19.69,254827,DB01043,Memantine
,18498913,C(ssmin),"The main pharmacokinetic parameters found for memantine at doses of 5 mg once daily for 14 days were as follows: T(max), 6.80 (2.46) h; C(ssmax), 19.69 (2.00) ng/mL; C(ssmin), 12.76 (2.80) ng/mL; C(ssav), 16.10 (2.46) ng/mL; t(1/2), 64.57 (15.78) h; MRT, 93.17 (23.38) h; AUC(ss),386.37 (59.00) ng x h/mL; and DF, 44.47% (15.27%).",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[ng] / [ml],12.76,254828,DB01043,Memantine
,18498913,C(ssav),"The main pharmacokinetic parameters found for memantine at doses of 5 mg once daily for 14 days were as follows: T(max), 6.80 (2.46) h; C(ssmax), 19.69 (2.00) ng/mL; C(ssmin), 12.76 (2.80) ng/mL; C(ssav), 16.10 (2.46) ng/mL; t(1/2), 64.57 (15.78) h; MRT, 93.17 (23.38) h; AUC(ss),386.37 (59.00) ng x h/mL; and DF, 44.47% (15.27%).",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[ng] / [ml],16.10,254829,DB01043,Memantine
,18498913,t(1/2),"The main pharmacokinetic parameters found for memantine at doses of 5 mg once daily for 14 days were as follows: T(max), 6.80 (2.46) h; C(ssmax), 19.69 (2.00) ng/mL; C(ssmin), 12.76 (2.80) ng/mL; C(ssav), 16.10 (2.46) ng/mL; t(1/2), 64.57 (15.78) h; MRT, 93.17 (23.38) h; AUC(ss),386.37 (59.00) ng x h/mL; and DF, 44.47% (15.27%).",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,64.57,254830,DB01043,Memantine
,18498913,MRT,"The main pharmacokinetic parameters found for memantine at doses of 5 mg once daily for 14 days were as follows: T(max), 6.80 (2.46) h; C(ssmax), 19.69 (2.00) ng/mL; C(ssmin), 12.76 (2.80) ng/mL; C(ssav), 16.10 (2.46) ng/mL; t(1/2), 64.57 (15.78) h; MRT, 93.17 (23.38) h; AUC(ss),386.37 (59.00) ng x h/mL; and DF, 44.47% (15.27%).",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,93.17,254831,DB01043,Memantine
,18498913,AUC(ss),"The main pharmacokinetic parameters found for memantine at doses of 5 mg once daily for 14 days were as follows: T(max), 6.80 (2.46) h; C(ssmax), 19.69 (2.00) ng/mL; C(ssmin), 12.76 (2.80) ng/mL; C(ssav), 16.10 (2.46) ng/mL; t(1/2), 64.57 (15.78) h; MRT, 93.17 (23.38) h; AUC(ss),386.37 (59.00) ng x h/mL; and DF, 44.47% (15.27%).",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[h·ng] / [ml],386.37,254832,DB01043,Memantine
,18498913,DF,"The main pharmacokinetic parameters found for memantine at doses of 5 mg once daily for 14 days were as follows: T(max), 6.80 (2.46) h; C(ssmax), 19.69 (2.00) ng/mL; C(ssmin), 12.76 (2.80) ng/mL; C(ssav), 16.10 (2.46) ng/mL; t(1/2), 64.57 (15.78) h; MRT, 93.17 (23.38) h; AUC(ss),386.37 (59.00) ng x h/mL; and DF, 44.47% (15.27%).",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),%,44.47,254833,DB01043,Memantine
